Bevisgjennomganger og White Papers
CTSB enables the next step of normal life to resume: Usage of LumiraDx SARS-CoV-2 Ag Pool Test supports opening strategies for social events in Germany
Performance of a SARS-CoV-2 Antigen Pool Test to aid diagnosis of acute COVID-19 at the point of care
The LumiraDx SARS-CoV-2 Antigen Test demonstrated as more sensitive compared to SD Biosensor Standard Q COVID-19 Rapid Antigen Test in an independent evaluation on behalf of the Swiss Federal Office of Public Health
The LumiraDx SARS-CoV-2 Antigen Test aligns with detection of infectious samples from immunocompetent individuals with none to mild and moderate symptoms
Summary of the Evaluation of 32 rapid tests for detection of IgG antibodies against SARS-CoV-2 (NOKLUS)
Establishing an Anticoagulation “Drive Through” Clinic during the COVID-19 Pandemic using the LumiraDx Platform INR Test
An evaluation of the detection of SARS-CoV-2 antigen in a cohort of symptomatic and asymptomatic patients: Report from the evaluation of SKUP
Performance evaluation of the LumiraDx SARS-CoV-2 Antigen Test to aid diagnosis of acute COVID-19 at the point of care
Evaluation of the Accuracy of the LumiraDx INR Test Using Patients in Receipt of Phenprocoumon Anticoagulation Therapy
Evaluation of the Accuracy of INR values measured by a POCT system in a German Clinic with patients taking Phenprocoumon as VKA Therapy.
Laboratory accuracy assessment of a novel INR Point-of-Care Test compared with laboratory reference methods used across four independent clinical sites.
Product Evaluation of the LumiraDx Platform and INR Test at the medical practice Dres. Schreiber, Steinbauer & Dechant
Performance of the LumiraDx Platform INR Test in a point-of-care setting compared to an established laboratory reference method